Loading
NASDAQHealthcareMedical - Devices
Latest quote
$3.96
−$0.17 · -4.12%
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Regular session
$3.96
−$0.17 · -4.12%
Regular session · ET · Market data may be delayed.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Day range
Current $3.96
52-week range
Current $3.96
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
77
Undervalued
Sentiment
54
Mixed
Risk
62
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Day range
Current $3.96
52-week range
Current $3.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 45.15M USD | 29.43M USD | 18.51M USD | 12.4M USD | 8.4M USD |
| Cost of goods sold | 6.97M USD | 4.1M USD | 2.61M USD | 2.26M USD | 1.19M USD |
| Gross profit | 38.19M USD | 25.33M USD | 15.91M USD | 10.14M USD | 7.21M USD |
| Research and development | 14.97M USD | 17.69M USD | 29.84M USD | 21.36M USD | 14.22M USD |
| Selling, general, and administrative | 50.17M USD | 43.81M USD | 40.55M USD | 25.22M USD | 17.02M USD |
| Operating expenses | 65.13M USD | 61.49M USD | 70.38M USD | 46.58M USD | 31.24M USD |
| Interest income | 555K USD | 404K USD | 431K USD | 180K USD | — |
| Interest expense | 5.54M USD | 3.09M USD | 16K USD | 1K USD | 1.76M USD |
| Depreciation and amortization | 626K USD | 744K USD | 684K USD | 398K USD | 464K USD |
| Operating income | −26.95M USD | −36.17M USD | −54.48M USD | −36.44M USD | −24.03M USD |
| Net income | −39.23M USD | −33.23M USD | −59.36M USD | −47.19M USD | −28.85M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
177.78% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.65M0.00%2.3T USD0.03%$381.91+0.62%
iShares Russell 2000 ETFIWM4.71M0.01%77.7B USD0.19%$279.3+0.62%
Vanguard Extended Market ETFVXF2.7M0.00%95.4B USD0.05%$235.14+0.86%
iShares Russell 2000 Growth ETFIWO1.71M0.01%14.04B USD0.24%$357.24+1.07%
Vanguard Russell 2000 ETFVTWO1.36M0.01%18B USD0.06%$112.81+0.63%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS1.24M0.31%396.33M USD0.60%$107.45+1.59%
iShares Micro-Cap ETFIWC573.54K0.04%1.32B USD0.60%$183.23+0.24%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM260K0.23%116.54M USD0.73%$15.94+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
